Adamas Pharmaceuticals, Inc.'s (ADMS) CEO Neil McFarlane on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s DiseaseGlobeNewsWire • 02/11/20
Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020GlobeNewsWire • 01/08/20
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking ImpairmentGlobeNewsWire • 12/17/19
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor ConferencesGlobeNewsWire • 11/21/19
Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/08/19
Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/19
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/31/19
Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International CongressGlobeNewsWire • 09/20/19
Adamas Pharmaceuticals, Inc. (ADMS) CEO Gregory Went on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19